Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study

TP. Hughes, G. Saglio, J. Geissler, DW. Kim, E. Lomaia, J. Mayer, A. Turkina, S. Kapoor, AP. Cardoso, B. Nieman, S. Quenet, JE. Cortes

. 2024 ; 17 (1) : 125. [pub] 20241218

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, klinické zkoušky, fáze II, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003008

BACKGROUND: Up to 65% of patients with chronic myeloid leukemia (CML) who are treated with imatinib do not achieve sustained deep molecular response, which is required to attempt treatment-free remission. Asciminib is the only approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket. This unique mechanism of action allows asciminib to be combined with adenosine triphosphate-competitive tyrosine kinase inhibitors to prevent resistance and enhance efficacy. The phase II ASC4MORE trial investigated the strategy of adding asciminib to imatinib in patients who have not achieved deep molecular response with imatinib. METHODS: In ASC4MORE, 84 patients with CML in chronic phase not achieving deep molecular response after ≥ 1 year of imatinib therapy were randomized to asciminib 40 or 60 mg once daily (QD) add-on to imatinib 400 mg QD, continued imatinib 400 mg QD, or switch to nilotinib 300 mg twice daily. RESULTS: More patients in the asciminib 40- and 60-mg QD add-on arms (19.0% and 28.6%, respectively) achieved MR4.5 (BCR::ABL1 ≤ 0.0032% on the International Scale) at week 48 (primary endpoint) than patients in the continued imatinib (0.0%) and switch to nilotinib (4.8%) arms. Fewer patients discontinued asciminib 40- and 60-mg QD add-on treatment (14.3% and 23.8%, respectively) than imatinib (76.2%, including crossover patients) and nilotinib (47.6%). Asciminib add-on was tolerable, with rates of AEs and AEs leading to discontinuation less than those with nilotinib, although higher than those with continued imatinib (as expected in these patients who had already been tolerating imatinib for ≥ 1 year). No new or worsening safety signals were observed with asciminib add-on vs the known asciminib monotherapy safety profile. CONCLUSIONS: Overall, these results support asciminib add-on as a treatment strategy to help patients with CML in chronic phase stay on therapy to safely achieve rapid and deep response, although further investigation is needed before this strategy is incorporated into clinical practice. TRIAL REGISTRATION: NCT03578367.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003008
003      
CZ-PrNML
005      
20250206104013.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13045-024-01642-6 $2 doi
035    __
$a (PubMed)39696526
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hughes, Timothy P $u South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia. Tim.Hughes@sahmri.com
245    10
$a Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study / $c TP. Hughes, G. Saglio, J. Geissler, DW. Kim, E. Lomaia, J. Mayer, A. Turkina, S. Kapoor, AP. Cardoso, B. Nieman, S. Quenet, JE. Cortes
520    9_
$a BACKGROUND: Up to 65% of patients with chronic myeloid leukemia (CML) who are treated with imatinib do not achieve sustained deep molecular response, which is required to attempt treatment-free remission. Asciminib is the only approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket. This unique mechanism of action allows asciminib to be combined with adenosine triphosphate-competitive tyrosine kinase inhibitors to prevent resistance and enhance efficacy. The phase II ASC4MORE trial investigated the strategy of adding asciminib to imatinib in patients who have not achieved deep molecular response with imatinib. METHODS: In ASC4MORE, 84 patients with CML in chronic phase not achieving deep molecular response after ≥ 1 year of imatinib therapy were randomized to asciminib 40 or 60 mg once daily (QD) add-on to imatinib 400 mg QD, continued imatinib 400 mg QD, or switch to nilotinib 300 mg twice daily. RESULTS: More patients in the asciminib 40- and 60-mg QD add-on arms (19.0% and 28.6%, respectively) achieved MR4.5 (BCR::ABL1 ≤ 0.0032% on the International Scale) at week 48 (primary endpoint) than patients in the continued imatinib (0.0%) and switch to nilotinib (4.8%) arms. Fewer patients discontinued asciminib 40- and 60-mg QD add-on treatment (14.3% and 23.8%, respectively) than imatinib (76.2%, including crossover patients) and nilotinib (47.6%). Asciminib add-on was tolerable, with rates of AEs and AEs leading to discontinuation less than those with nilotinib, although higher than those with continued imatinib (as expected in these patients who had already been tolerating imatinib for ≥ 1 year). No new or worsening safety signals were observed with asciminib add-on vs the known asciminib monotherapy safety profile. CONCLUSIONS: Overall, these results support asciminib add-on as a treatment strategy to help patients with CML in chronic phase stay on therapy to safely achieve rapid and deep response, although further investigation is needed before this strategy is incorporated into clinical practice. TRIAL REGISTRATION: NCT03578367.
650    _2
$a lidé $7 D006801
650    12
$a imatinib mesylát $x terapeutické užití $7 D000068877
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a chronická myeloidní leukemie $x farmakoterapie $7 D015464
650    _2
$a dospělí $7 D000328
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a senioři $7 D000368
650    _2
$a následné studie $7 D005500
650    _2
$a pyrimidiny $x terapeutické užití $x aplikace a dávkování $7 D011743
650    _2
$a výsledek terapie $7 D016896
650    _2
$a inhibitory proteinkinas $x terapeutické užití $x aplikace a dávkování $7 D047428
650    _2
$a bcr-abl fúzní proteiny $x antagonisté a inhibitory $7 D016044
650    _2
$a niacinamid $x analogy a deriváty $7 D009536
650    _2
$a pyrazoly $7 D011720
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Saglio, Giuseppe $u Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
700    1_
$a Geissler, Jan $u CML Advocates Network, Bern, Switzerland
700    1_
$a Kim, Dong-Wook $u Uijeongbu Eulji Medical Center, Geumo-Dong, Uijeongbu-si, South Korea
700    1_
$a Lomaia, Elza $u Almazov National Medical Research Centre, St Petersburg, Russia
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University, and University Hospital Brno, Brno, Czech Republic
700    1_
$a Turkina, Anna $u National Medical Research Center for Hematology, Moscow, Russia
700    1_
$a Kapoor, Shruti $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Cardoso, Ana Paula $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Nieman, Becki $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Quenet, Sara $u Novartis Pharmaceuticals Corporation, Basel, Switzerland
700    1_
$a Cortes, Jorge E $u Georgia Cancer Center, Augusta, GA, USA
773    0_
$w MED00165458 $t Journal of hematology & oncology $x 1756-8722 $g Roč. 17, č. 1 (2024), s. 125
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39696526 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104008 $b ABA008
999    __
$a ok $b bmc $g 2263038 $s 1239015
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 17 $c 1 $d 125 $e 20241218 $i 1756-8722 $m Journal of hematology & oncology $n J Hematol Oncol $x MED00165458
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace